Dette prosjektet vil forene forskning og utdanning som skjer ved Universitetet i Oslo, Stanford University og University of Chicago rundt sykdommen cøliaki. I de siste årene er det skjedd store fremskritt i forståelsen av hva som går galt når sykdommen utvikles, og mange av oppdagelsene er gjort av partnere i prosjektet. Til tross for fremskrittene er det mye som er uoppdaget. Det er fortsatt mange udekkede medisinske behov ved tilstanden. Prosjektet har som mål å øke forståelsen av sykdommen og å utvikle nye terapier.
TransCeliac - a partnership on medical research and education - is planned to serve as a framework for long-term collaboration between University of Oslo/Oslo University Hospital and two top-tier US Universities; University of Chicago and Stanford University. Research groups at the three institutions are world-leading in the area of celiac disease research, and these research groups have enjoyed collaborations in the past. A reinforcement of already existing relationships through INTPART will expand and strengthen the quality of the collaboration and strongly lift education of students.
Activities at Stanford University will be centered on Stanford ChEM-H which builds on Stanford's extraordinary talent in the Schools of Humanities & Sciences, Engineering, and Medicine. This program has the ambition to educate a new generation of researchers who are fluent in both chemistry and biology. The University of Chicago has premier PhD programs that combines expertise in computational biology, immunology and experimental microbiome research. Transfer of knowledge and experience from the interdisciplinary training programs will be used to develop the PhD program and the UiO:Life Science program at UiO. The activities at the University of Oslo will be centered around the UiO Immunology World Leading Research Community. This is one of five research communities that UiO's Vice-Chancellor has selected to further develop world leading research and education at this institution.
Celiac disease is a disorder caused by harmful immune response to cereal gluten proteins. Huge advances in the understanding of disease mechanisms have been made recently by partners of the project. Despite improved insight much remains undiscovered, and there are large unmet medical needs for the condition. The focus of the project is to advance the understanding of the pathogenesis of the disease and specifically to decipher the role of transglutaminase 2 with the aim to develop new therapies.